Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision MedicineChantal Pauli, Mark A. Rubin, Benjamin D. Hopkins et al.|Cancer Discovery|2017Cited by 964
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y.L. Lui, Carla Grandori, Reid Shaw et al.|EBioMedicine|2020Cited by 38
Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck CancerChang Xu, Eduardo Méndez, Christopher J. Kemp et al.|Clinical Cancer Research|2018Cited by 25
Predictive value of a CLIA-approved organoid based drug sensitivity test.Astrid Margossian, Carla Grandori, Annie Richardson et al.|Journal of Clinical Oncology|2020Cited by 6
A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.Astrid Margossian, Carla Grandori, Madison Pollastro et al.|Journal of Clinical Oncology|2021Cited by 4